Skip to main content

Advertisement

Log in

Adalimumab for juvenile idiopathic arthritis-associated uveitis

  • Inflammatory Disorders
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To assess the long-term outcomes and complications of patients with uveitis from juvenile idiopathic arthritis (JIA) treated with adalimumab.

Methods

Prospective interventional case series. All patients who underwent treatment with adalimumab for JIA and anterior uveitis were prospectively included in the study. The anterior chamber inflammation was evaluated according to the Standardization of Uveitis Nomenclature criteria.

Results

Twenty-one patients (16 females, five males, 38 eyes) were included in the study. Mean age of patients at referral was 11.1 ± 3.8 (5–17) years. Before initiation of treatment, mean duration of arthritis was 7.0 ± 5.5 (median, 6) months, mean duration of uveitis was 7.0 ± 4.4 (median, 7) months. Oligoarticular arthritis was present in 15 cases (71 %), polyarticular arthritis in six cases (28 %). After a mean follow-up of 18.2 ± 7.7 (9–41) months, resolution of anterior chamber inflammation was obtained in 29/38 eyes (76 %). The anterior uveitis flare rate during the 12 months prior to enrollment was 1.6 ± 0.4/year, and was reduced during adalimumab treatment to 0.7 ± 0.3/year (p < 0.001). A significant decrease of the number of relapses/month was present after onset of treatment with adalimumab (0.18 ± 0.2 before versus 0.02 ± 0.1 after treatment onset, p < 0.001). No significant correlation was found between relapse number and age, sex, type of JIA and doses of previous steroid treatment (p > 0.05).

Conclusion

Adalimumab showed to be effective and relatively safe for treatment of JIA-associated uveitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Levinson JE, Wallace CA (1992) Dismantling the pyramid. J Rheumatol 33(Suppl):6–10

    CAS  Google Scholar 

  2. Ruperto N, Levinson JE, Ravelli A, Shear ES, Link Tague B, Murray K, Martini A, Giannini EH (1997) Long term health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 24:945–951

    PubMed  CAS  Google Scholar 

  3. Kanski JJ (1990) Juvenile arthritis and uveitis. Surv Ophthalmol 34:253–267

    Article  PubMed  CAS  Google Scholar 

  4. Kotaniemi K, Savolainen A, Karma A, Aho K (2003) Major review. Recent advances in uveitis of juvenile idiopathic arthritis. Surv Ophthalmol 48:489–502

    Article  PubMed  Google Scholar 

  5. Zannin ME, Buscain I, Vittadello F, Martini G, Alessio M, Orsoni JG, Breda L, Rigante D, Cimaz R, Zulian F (2012) Timing of uveitis onset in oligoarticular juvenile idiopathic arthritis (JIA) is the main predictor of severe course uveitis. Acta Ophthalmol 90:91–95

    Article  PubMed  CAS  Google Scholar 

  6. Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, Gómez Vidal MA, Collantes Estévez E, Ramírez Chamond R, Omar M (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251–255

    Article  PubMed  CAS  Google Scholar 

  7. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, Rosenbaum JT (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45:252–257

    Article  PubMed  CAS  Google Scholar 

  8. Lovell D (2004) Biological agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatric Drugs 6:137–146

    Article  PubMed  Google Scholar 

  9. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN (2008) Biologics for the treatment of juvenile idiopathic arthritis: a systemic review and critical analysis of the evidence. Clin Rheumatol 27:67–76

    Article  PubMed  Google Scholar 

  10. Beresford MW, Baildam EM (2009) New advances in the management of juvenile idiopathic arthritis. 2: the era of biologicals. Arch Dis Child Educ Pract Ed 94:151–156

    Article  PubMed  CAS  Google Scholar 

  11. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH, Pediatric Rheumatology Collaborative Study Group (2008) Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile idiopathic arthritis. Arthritis Rheum 58:1496–1504

    Article  PubMed  CAS  Google Scholar 

  12. Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D, Schmeling H, German and Austrian Paediatric Rheumatology Collaborative Study Group (2009) Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German registry. Ann Rheum Dis 68:519–525

    Article  PubMed  CAS  Google Scholar 

  13. Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW (2009) Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 68:635–641

    Article  PubMed  CAS  Google Scholar 

  14. Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66:548–550

    Article  PubMed  Google Scholar 

  15. Kahn P, Weiss M, Imundo LF, Levy DM (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmol 113:860–864, Epub 15 March 2006

    Article  Google Scholar 

  16. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903–912

    Article  PubMed  CAS  Google Scholar 

  17. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113:308–314

    Article  PubMed  Google Scholar 

  18. Sukumaran S, Marzan K, Shaham B, Reiff A (2012) High dose infliximab in the treatment of refractory uveitis: does dose matter? Rheumatol Jan 5. doi:10.5402/2012/765380

  19. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91:319–324

    Article  PubMed  Google Scholar 

  20. Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34:1146–1150

    PubMed  CAS  Google Scholar 

  21. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209

    PubMed  CAS  Google Scholar 

  22. Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, Maldonado-Cocco J, Suarez-Almazor M, Orozco-Alcala J, Prieur AM (1998) Revision of the proposal classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 25:1991–1994

    PubMed  CAS  Google Scholar 

  23. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) working group. Standardization of Uveitis Nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140:509–516

    Article  PubMed  Google Scholar 

  24. Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, Cimino L, Zannin ME (2010). Abatacept for severe anti-TNF alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62(6):821–825

    Article  CAS  Google Scholar 

  25. Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero-Coma M, Ortega G, Ortego N, Suarez-de-Figueroa M, Rio-Pardo MJ, Fernandez-Cid C, Fonollosa A, Blanco R, Garcia-Aparicio AM, Benitez-Del-Castillo JM, Olea JL, Arevalo JF (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119:1575–1581

    Article  PubMed  Google Scholar 

  26. Tynjälä P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, Lahdenne P (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 47:339–344

    Article  Google Scholar 

  27. Kotaniemi K, Säilä H, Kautiainen H (2011) Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clin Ophthalmol 5:1425–1429

    Article  PubMed  CAS  Google Scholar 

  28. Vazquez-Cobian LB, Flynn T, Lehman TJ (2006) Adalimumab therapy for childhood uveitis. J Pediatr 149:572–575

    Article  PubMed  CAS  Google Scholar 

  29. Simonini G, Taddio A, Cattalini M, Caputo R, De Libero C, Naviglio S, Bresci C, Lorusso M, Lepore L, Cimaz R (2011) Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus Infliximab. Arthritis Care Res (Hoboken) 63:612–618

    Article  CAS  Google Scholar 

  30. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG (2006) Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheum Dis 65:753–759

    Article  PubMed  CAS  Google Scholar 

  31. Wolf MD, Lichter PR, Ragsdale CG (1987) Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology 94:1242–1248

    PubMed  CAS  Google Scholar 

  32. Kanski JJ (1992) Lensectomy for complicated cataract in juvenile chronic iridocyclitis. Br J Ophthalmol 76:72–75

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Raimondo Forte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Magli, A., Forte, R., Navarro, P. et al. Adalimumab for juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol 251, 1601–1606 (2013). https://doi.org/10.1007/s00417-013-2275-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-013-2275-x

Keywords

Navigation